2016 Announcements


18 October 2016

 CLINUVEL [ASX: CUV; Nasdaq International Designation ADR: CLVLY; Xetra-DAX: UR9] today announced an update on the review by National Institute for Health and Care Excellence (NICE) regarding its drug SCENESSE® (afamelanotide 16mg) for adult patients with erythropoietic protoporphyria (EPP) in England.

On 24 March 2016 CLINUVEL announced it had participated in a public workshop with NICE where it had proposed SCENESSE® to be evaluated under the Highly Specialised Technology (HST) Programme for its introduction in England. HST evaluations are recommendations on the use of new and existing highly specialised medicines and treatments within the NHS in England. The HST programme only considers drugs for very rare conditions.

Download PDF

Go To Top